Tareq Al Baghdadi, MD | Oncologist in ...

Dr. Tareq Al Baghdadi

Claim this profile

Genesys Hurley Cancer Institute

Expert in Cancer
Expert in Pancreatic Cancer
73 reported clinical trials
130 drugs studied

About Tareq Al Baghdadi

Education:

  • Earned a Medical Degree (MD) from an unspecified medical school.
  • Completed a Residency in Internal Medicine at Saint Joseph Mercy Hospital, also serving as Chief Resident.
  • Undertook a Fellowship in Cardiovascular Disease at Saint Joseph Mercy Hospital.

Experience:

  • N/A

Area of expertise

1

Cancer

Global Leader

Tareq Al Baghdadi has run 18 trials for Cancer. Some of their research focus areas include:

Stage IV
KRAS positive
Stage III
2

Pancreatic Cancer

Global Leader

Tareq Al Baghdadi has run 11 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
KRAS positive
Stage III

Affiliated Hospitals

Image of trial facility.

Genesys Hurley Cancer Institute

Image of trial facility.

Trinity Health Saint Mary Mercy Livonia Hospital

Clinical Trials Tareq Al Baghdadi is currently running

Image of trial facility.

Atezolizumab + Chemotherapy

for Neuroendocrine Carcinoma

This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.

Recruiting

1 award

Phase 2 & 3

10 criteria

Image of trial facility.

Venetoclax + HMA

for Acute Myeloid Leukemia

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.

Recruiting

1 award

Phase 2

7 criteria

More about Tareq Al Baghdadi

Clinical Trial Related

9 years of experience running clinical trials · Led 73 trials as a Principal Investigator · 25 Active Clinical Trials

Treatments Tareq Al Baghdadi has experience with

  • Pembrolizumab
  • Atezolizumab
  • Cisplatin
  • Nivolumab
  • Fluorouracil
  • Carboplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Tareq Al Baghdadi specialize in?

Is Tareq Al Baghdadi currently recruiting for clinical trials?

Are there any treatments that Tareq Al Baghdadi has studied deeply?

What is the best way to schedule an appointment with Tareq Al Baghdadi?

What is the office address of Tareq Al Baghdadi?

Is there any support for travel costs?